Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.
Heerding, D.A., Rhodes, N., Leber, J.D., Clark, T.J., Keenan, R.M., Lafrance, L.V., Li, M., Safonov, I.G., Takata, D.T., Venslavsky, J.W., Yamashita, D.S., Choudhry, A.E., Copeland, R.A., Lai, Z., Schaber, M.D., Tummino, P.J., Strum, S.L., Wood, E.R., Duckett, D.R., Eberwein, D., Knick, V.B., Lansing, T.J., McConnell, R.T., Zhang, S., Minthorn, E.A., Concha, N.O., Warren, G.L., Kumar, R.(2008) J Med Chem 51: 5663-5679
- PubMed: 18800763 
- DOI: https://doi.org/10.1021/jm8004527
- Primary Citation of Related Structures:  
3D0E - PubMed Abstract: 
Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT ...